Why is Savara stock plunging today?

Savara (SVRA) stock fell 21.7% pre-market after the FDA delayed its decision on molgramostim, a treatment for a rare lung disease, without setting a new timeline. The stock had risen to $5.21 ahead of the expected decision. Analysts maintain Buy ratings with targets of $10-$11, but uncertainty looms. The broader market decline also pressured the stock, which traded at $4.08, near its 52-week low.

Original reporting
Published Nov 20, 2026, 1:44 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 20, 2026, 2:16 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefMarket movers
Primary signal
$SVRA
Bearish
high confidence
Mentioned
$SVRA
Relevance
9/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$SVRABearishHigh
01

Why it matters

The unexpected delay removes the catalyst that drove recent gains, likely leading to continued downside pressure.

02

Market read

The news directly caused a >20% pre‑market drop, making it a high‑impact, actionable event for traders.

03

What to watch

Potential positive data from European/UK regulators could mitigate U.S. delay risk.

Relevance 9/10Novelty 9/10Timing: pre‑market today

Background

Savara had rallied on expectations of FDA approval for its inhaled molgramostim therapy for autoimmune pulmonary alveolar proteinosis.

Company-level read

Ticker impact

$SVRABearishHigh confidence
Context

FDA announced it will not meet the Nov 22 PDUFA target for Savara's molgramostim BLA, causing a 21.7% pre‑open plunge.

Expected impact

downward pressure as investors price in the open‑ended regulatory timeline

Evidence & confidence

A 20%+ pre‑market drop on a fresh regulatory setback is a strong sell signal for a clinical‑stage biotech.

Market effects

Biotech stocks with pending FDA decisions may face broader weakness.

Nasdaq down 2.1%, S&P 500 down 1.1% as risk‑off sentiment spreads.

Limited to U.S. biotech sector; no immediate global macro impact.

Counterpoint

If Savara secures a new FDA target date soon, the stock could rebound sharply.

Key entities

  • Savara Inc.

    Clinical‑stage biopharma developing molgramostim.

  • U.S. Food and Drug Administration

    Agency responsible for approving the BLA.

Related articles

$SVRAMed

FDA to miss deadline on Savara's rare lung disease drug approval

Savara Inc. announced the FDA will miss its November 22 deadline to decide on its rare lung disease drug, molgramostim. The company's shares fell 16% in premarket trading. The FDA did not provide a new decision date, and Savara's application remains under review. Molgramostim is an experimental treatment for autoimmune pulmonary alveolar proteinosis, with no FDA-approved treatments currently available.

$SVRAMed

FDA delays decision on Savara’s autoimmune PAP treatment

Savara Inc. (SVRA) reported the FDA delayed its decision on the company's molgramostim treatment for autoimmune PAP, missing the November 2026 target date. The FDA is still reviewing the application and has not set a new timeline. Savara's CEO expressed commitment to working with the agency. Molgramostim is an investigational treatment for a rare lung disease, not yet approved by the FDA.

$SVRAMedAI 8/10

Savara Reports Molgramostim Benefits in Exploratory Lung Study

Savara Inc. (SVRA) reported improvements in lung function and imaging measures in a small subgroup of patients with autoimmune pulmonary alveolar proteinosis (aPAP) treated with molgramostim, according to a retrospective analysis presented at CHEST 2026. The analysis included 11 patients and showed a 12.7 mmHg improvement in the alveolar-arterial oxygen gradient for molgramostim recipients compared to 0.3 mmHg for placebo. The company noted the findings are exploratory and not definitive.